Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney


Jorge A. Garcia, MD

Status and phase

Phase 2


Kidney Cancer


Biological: aldesleukin
Biological: bevacizumab

Study type


Funder types



CASE8804 (Other Identifier)
P30CA043703 (U.S. NIH Grant/Contract)
7493 (Other Identifier)

Details and patient eligibility


RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Biological therapies, such as aldesleukin, may stimulate the immune system in different ways and stop tumor cells from growing. Giving bevacizumab together with aldesleukin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with aldesleukin works in treating patients with metastatic clear cell carcinoma of the kidney.

Full description

OBJECTIVES: Primary To evaluate the effect of the combination of bevacizumab and aldesleukin on progression-free survival of patients with good- or intermediate-risk metastatic clear cell renal cell carcinoma. Secondary To determine the objective response rate in patients receiving this regimen. To determine the time to progression in patients receiving this regimen. To evaluate immunomodulatory effects of this regimen in patients To evaluate the toxicity of this regimen in these patients. OUTLINE: Patients receive bevacizumab IV over 30-90 minutes on days -14, 1, 15, 29, and 42 and aldesleukin subcutaneously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving complete response after completion of study therapy may receive 1 additional course of therapy. After completion of study therapy, patients are followed periodically.


26 patients




18 to 120 years old


No Healthy Volunteers

Inclusion and exclusion criteria


  • Histologically or cytologically confirmed renal cell carcinoma (RCC) of clear cell histology with or without sarcomatoid features

    • Metastatic disease
    • No non-clear cell RCC (i.e., papillary, collecting-duct, or chromophobe)
  • Good- or intermediate-risk category as defined by having ≤ 2 of the following factors:

    • No prior nephrectomy
    • Karnofsky performance status < 80%
    • Hemoglobin < 12 g/dL
    • Corrected calcium > 10.0 mg/dL
    • LDH > 1.5 times upper limit of normal (ULN)
  • Must have undergone a nephrectomy at least 28 days ago

  • Measurable or evaluable disease by RECIST

  • No significant effusions and/or ascites

  • No prior or concurrent brain or CNS metastasis


  • ECOG performance status 0-1

  • Life expectancy of ≥ 3 months

  • WBC ≥ 3,000/mm^3

  • Platelet count ≥ 100,000/mm^3

  • Hemoglobin ≥ 9.5 g/dL

  • Creatinine ≤ 2.0 mg/dL

  • Total bilirubin ≤ 1.5 mg/dL

  • AST ≤ 5.0 times ULN

  • Alkaline phosphatase ≤ 2.5 times ULN (≤ 10 times ULN with bone metastasis)

  • Calcium ≤ 12 mg/dL

  • Urine protein:creatinine ratio ≤ 1.0

  • INR ≤ 1.5 (unless receiving warfarin therapy)

  • Not pregnant or nursing

  • Negative pregnancy test

  • Fertile patients must use effective contraception

  • No uncontrolled seizure disorder

  • No known HIV positivity

  • No local or systemic infections requiring IV antibiotics within the past 28 days

  • No significant traumatic injury in the past 28 days

  • No serious non-healing wound, ulcer, or acute bone fracture

  • No evidence of bleeding diathesis or coagulopathy

  • No other malignancy except basal cell or squamous cell carcinoma of the skin, carcinoma in-situ of the uterine cervix, or any malignancy treated with curative intent and in complete remission for > 3 years

  • No history of serious systemic or severe cardiovascular disease, including any of the following:

    • Arterial thromboembolic event (including transient ischemic attack)
    • Cerebrovascular accident
    • Unstable angina
    • Myocardial infarction within the past 6 months
    • Uncontrolled hypertension (BP > 160/110 mm Hg on medication)
    • Uncontrolled cardiac arrhythmia
    • Congestive heart failure
    • Angina pectoris
    • NYHA class III-IV cardiovascular disease
    • Peripheral vascular disease ≥ grade II
  • No history of abdominal fistula and/or bowel or gastric perforation within the past 6 months

  • No history of other diseases, metabolic dysfunction, or physical or laboratory examination findings giving reasonable suspicion of a disease or condition that contraindicate the use of investigational drugs, or that might affect the interpretation of study results, or that render patient at high-risk for treatment complications


  • See Disease Characteristics

  • No prior organ allografts

  • No prior systemic therapy for metastatic clear cell renal cell carcinoma

  • At least 4 weeks since prior radiotherapy and recovered

    • Radiotherapy for control of pain from skeletal lesions allowed within the past 28 days
  • More than 12 months since prior adjuvant therapy

  • More than 7 days since prior fine-needle aspirations or core biopsies

  • More than 28 days since prior and no concurrent major surgery requiring general anesthesia or open biopsy

  • No concurrent aspirin, corticosteroids (except at replacement doses), barbiturates, or other investigational agents

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

26 participants in 1 patient group

Bevacizumab and Aldesleukin
Experimental group
Biological: bevacizumab
Biological: aldesleukin

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems